Dr. Venook Discusses the Role of Chemotherapy in Metastatic CRC

Alan P. Venook, MD
Published: Thursday, May 11, 2017



Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of chemotherapy in metastatic colorectal cancer (CRC).

Chemotherapy isn’t particularly critical in the treatment of metastatic CRC, Venook says. What is more important is the choice of biologic in combination with chemotherapy.

There is a suggestion that there is a benefit with cetuximab (Erbitux) in patients with all RAS wildtype CRC in combination with chemotherapy. In a US study though, data showed that bevacizumab (Avastin) and cetuximab are essentially the same in this combination, Venook adds.
 
SELECTED
LANGUAGE


Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of chemotherapy in metastatic colorectal cancer (CRC).

Chemotherapy isn’t particularly critical in the treatment of metastatic CRC, Venook says. What is more important is the choice of biologic in combination with chemotherapy.

There is a suggestion that there is a benefit with cetuximab (Erbitux) in patients with all RAS wildtype CRC in combination with chemotherapy. In a US study though, data showed that bevacizumab (Avastin) and cetuximab are essentially the same in this combination, Venook adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x